# A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma

> **NCT06153251** · PHASE1 · RECRUITING · sponsor: **Juno Therapeutics, Inc., a Bristol-Myers Squibb Company** · enrollment: 187 (estimated)

## Conditions studied

- Relapsed and/or Refractory Multiple Myeloma

## Interventions

- **DRUG:** BMS-986453
- **DRUG:** Fludarabine
- **DRUG:** Cyclophosphamide

## Key facts

- **NCT ID:** NCT06153251
- **Lead sponsor:** Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-01-23
- **Primary completion:** 2030-05-02
- **Final completion:** 2030-05-02
- **Target enrollment:** 187 (ESTIMATED)
- **Last updated:** 2026-03-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06153251

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06153251, "A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06153251. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*